Skip to main content
Keyword
Specialties
Allergy & Immunology
Autoimmune
CardioVascular
Clinical Pathways
Dentistry
Dermatology
Emergency & Mobile Medicine
Endocrinology & Diabetes
Gastroenterology
Infectious Diseases
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Pediatrics
Podiatry
Population Health
Psychiatry & Behavioral Health
Pulmonology
Rheumatology & Arthritis
Surgery
Urology
Wound Care
Events
Education
About
Sign In
Search
Keyword
Specialties
Allergy & Immunology
Autoimmune
CardioVascular
Clinical Pathways
Dentistry
Dermatology
Emergency & Mobile Medicine
Endocrinology & Diabetes
Gastroenterology
Infectious Diseases
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Pediatrics
Podiatry
Population Health
Psychiatry & Behavioral Health
Pulmonology
Rheumatology & Arthritis
Surgery
Urology
Wound Care
Events
Education
About
Sign In
Search
I. Borbath
PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib vs gemcitabine + cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement
Background First-line treatment options are limited for patients with advanced cholangiocarcinoma (CCA). Genetic alterations in the fibroblast growth factor receptor (FG...
Teresa Macarulla , MD, PhD;
Sudipta Roychowdhury , MD;
R. Shroff ;
J. Soto ;
G. Pedrioli ;
L. Fumagalli ;
C. dambkowski ;
M. Javle ;
Ghassan Abou-Alfa , MD, MBA;
D. Oh ;
I. Borbath ;
Lovely Goyal ;
Angela Lamarca , MD, PhD, MSc;
06/27/2022
Featured CME Course
Targeted Therapies for the Management of Chronic Lymphocytic Leukemia: Evaluating the Evidence to Optimize Patient Care and Outcomes
Upcoming Events
February 2 – February 5
February 7 – February 9
February 27 – March 1
March 17 – March 19
March 22 – March 23
March 27 – March 30
March 31 – April 2
April 21 – April 24
April 30 – May 4
May 1 – May 3
See Full Calendar